Jeil Pharm Cash Flow Conversion Efficiency
Jeil Pharm cash flow conversion efficiency. Based on the latest financial reports, Jeil Pharm (002620) has a cash flow conversion efficiency ratio of -0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.71 Billion ≈ $-3.20 Million USD) by net assets (₩470.67 Billion ≈ $318.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jeil Pharm (2011–2025)
Cash flow conversion efficiency of Jeil Pharm from 2011 to 2025. This chart illustrates how Jeil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 002620 live share price for real-time trading data and today's change.
Jeil Pharm Cash Flow Conversion Ratio Explained
Jeil Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jeil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharm ranked by their cash flow conversion efficiency. Also see Jeil Pharm market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIMobject AB
ST:BIM
|
-0.108x |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
-0.011x |
|
Skarbiec Holding S.A.
WAR:SKH
|
-1.431x |
|
Powertech Industrial Co Ltd
TW:3296
|
-0.016x |
|
Daidong Elec
KO:008110
|
0.017x |
|
Julong Holding Limited Class A Ordinary Shares
NASDAQ:JLHL
|
-0.219x |
|
City Auto Corp
VN:CTF
|
0.100x |
|
Phillips 66
F:PSX
|
0.024x |
Annual Cash Flow Conversion Efficiency for Jeil Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jeil Pharm from 2011 to 2025. Review how much free cash does Jeil Pharm generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩469.12 Billion ≈ $317.91 Million |
₩390.26 Million ≈ $264.47K |
0.001x | -91.99% |
| 2024-12-31 | ₩437.40 Billion ≈ $296.42 Million |
₩4.54 Billion ≈ $3.08 Million |
0.010x | +194.59% |
| 2023-12-31 | ₩402.19 Billion ≈ $272.56 Million |
₩-4.42 Billion ≈ $-2.99 Million |
-0.011x | +77.84% |
| 2022-12-31 | ₩419.79 Billion ≈ $284.49 Million |
₩-20.80 Billion ≈ $-14.10 Million |
-0.050x | -284.97% |
| 2021-12-31 | ₩500.31 Billion ≈ $339.06 Million |
₩13.40 Billion ≈ $9.08 Million |
0.027x | +156.50% |
| 2020-12-31 | ₩499.28 Billion ≈ $338.36 Million |
₩-23.67 Billion ≈ $-16.04 Million |
-0.047x | -190.82% |
| 2019-12-31 | ₩483.04 Billion ≈ $327.35 Million |
₩25.22 Billion ≈ $17.09 Million |
0.052x | +996.58% |
| 2018-12-31 | ₩589.58 Billion ≈ $399.55 Million |
₩-3.43 Billion ≈ $-2.33 Million |
-0.006x | -116.75% |
| 2017-12-31 | ₩170.44 Billion ≈ $115.50 Million |
₩5.92 Billion ≈ $4.01 Million |
0.035x | -22.85% |
| 2016-12-31 | ₩252.08 Billion ≈ $170.83 Million |
₩11.36 Billion ≈ $7.70 Million |
0.045x | +296.38% |
| 2015-12-31 | ₩241.39 Billion ≈ $163.59 Million |
₩2.74 Billion ≈ $1.86 Million |
0.011x | +169.58% |
| 2012-12-31 | ₩241.41 Billion ≈ $163.60 Million |
₩-3.94 Billion ≈ $-2.67 Million |
-0.016x | -116.00% |
| 2011-12-31 | ₩231.40 Billion ≈ $156.81 Million |
₩23.63 Billion ≈ $16.01 Million |
0.102x | -- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more